Half year interim results FY19
Jayne Hrdlicka | Managing Director & CEO | 20 February 2019
Record results and step changing investment for the future

**Record financial results in 1H19, continuing strong momentum**
- Group revenue: $613.1 million\(^1\) +41.0%; EBITDA\(^2\): $218.4 million +52.7%
- Net profit after tax: $152.7 million +55.1%
- Strong balance sheet with closing cash balance: $287.9 million

**Record market share positions underpin strong results in each region**
- Infant formula consumption market share in China of 5.7%; China label revenue +82.6%, brand leadership in Australia at 35.7%\(^4\)
- US sales growth +114.1% (USD) and over 10k store distribution
- Australian fresh milk value share 10.8%; revenue +11.7% (AUD)

**Step changing investment for the long term health of our brand and core markets**
- Accelerating strategic investment in consumer insights, brand and organisational capability
- Marketing spend +75% in first half (#1 priority China, #2 priority USA)
- Number of new senior and broader team hires, focussing on China, NPD and capacity for continued growth and resilience
- Building both depth and breadth of organisational capability and infrastructure

---
\(^1\) All figures quoted in New Zealand Dollars (NZ$) and all comparisons are with the six months ended 31 December 2017 (1H18), unless otherwise stated
\(^2\) Operating EBITDA is a non-GAAP measure and represents earnings before interest, tax, depreciation and amortisation
\(^3\) Kantar Infant formula market tracking of China Tier 1 and Key A cities for 12 months ending 28 December 2018 by value
\(^4\) A2C Australian Grocery and Pharmacy Scan 12 months ending 30 December 2018
\(^5\) A2C Australian Grocery Weighted Scan 12 months ending 30 December 2018
Key financial charts\(^1\) – continuing strong momentum

### Group revenue (NZ$ million)
- **FY16**: 352.8
  - **H1**: 213.6
  - **H2**: 139.2
- **FY17**: 549.5
  - **H1**: 293.4
  - **H2**: 256.1
- **FY18**: 922.7
  - **H1**: 488.0
  - **H2**: 434.7
- **1H19**: 613.1
  - **H1**: 613.1

### Group EBITDA\(^2\) (NZ$ million)
- **FY16**: 54.6
  - **H1**: 54.6
  - **H2**: 0
- **FY17**: 141.2
  - **H1**: 77.1
  - **H2**: 64.1
- **FY18**: 283.0
  - **H1**: 143.0
  - **H2**: 140.0
- **1H19**: 218.4
  - **H1**: 218.4

### Basic Earnings Per Share (cents)
- **FY16**: 4.4
- **FY17**: 12.7
- **FY18**: 27.0
- **1H19**: 20.9

---

\(^1\) The Company’s financial year ends 30 June; H1 refers to the first half period from 1 July to 31 December; H2 refers to the second half period from 1 January to 30 June

\(^2\) EBITDA is a non-GAAP measure and represents earnings before interest, tax, depreciation and amortisation, and is shown before non-recurring items
# Financial summary – step changing investment

<table>
<thead>
<tr>
<th>NZ$ million</th>
<th>1H19</th>
<th>1H18</th>
<th>% change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>613.1</td>
<td>434.7</td>
<td>+41%</td>
</tr>
<tr>
<td>Gross margin</td>
<td>340.6</td>
<td>216.5</td>
<td>+57%</td>
</tr>
<tr>
<td>Distribution</td>
<td>(14.8)</td>
<td>(13.0)</td>
<td>+14%</td>
</tr>
<tr>
<td>Marketing</td>
<td>(45.5)</td>
<td>(26.0)</td>
<td>+75%</td>
</tr>
<tr>
<td>Employee costs</td>
<td>(27.4)</td>
<td>(16.4)</td>
<td>+67%</td>
</tr>
<tr>
<td>Administration &amp; other</td>
<td>(34.5)</td>
<td>(18.0)</td>
<td>+91%</td>
</tr>
<tr>
<td>EBITDA</td>
<td>218.4</td>
<td>143.0</td>
<td>+53%</td>
</tr>
<tr>
<td>EBIT</td>
<td>217.4</td>
<td>141.9</td>
<td>+53%</td>
</tr>
<tr>
<td>NPAT</td>
<td>152.7</td>
<td>98.5</td>
<td>+55%</td>
</tr>
</tbody>
</table>

- Reflects continuing strong growth across key regions
- GM of 55.6% reflects benefits of scale and mix (higher proportion of infant formula sales), partially offset by currency movements (most notably a weaker AUD)
- Increased marketing investment primarily to support growth in China and the US
- Employee cost increases reflect capability build in core markets and corporate
- Reflects strategic investment in consumer insights and costs to support business expansion

<table>
<thead>
<tr>
<th>NZ$ million</th>
<th>Dec-18</th>
<th>Jun-18</th>
<th>% change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash on hand</td>
<td>287.9</td>
<td>340.5</td>
<td>-15%</td>
</tr>
<tr>
<td>Inventory</td>
<td>72.8</td>
<td>64.1</td>
<td>+13%</td>
</tr>
</tbody>
</table>

- Cash on hand reflects strong NPAT contribution, offset by investment in Synlait
- Increase in infant formula inventories; includes $35.3m of goods in transit
Cash position – strong balance sheet

Group cash movement: 1H19
(NZ$ million)

- Working capital movement reflects timing of tax and supplier payments, impact of revenue phasing on debtors and increased infant formula inventory
- Increased investment in Synlait to 17.4% shareholding in August 2018
# Geographic and product segment performance

<table>
<thead>
<tr>
<th></th>
<th>Geographic segment revenue &amp; EBITDA</th>
<th>Product segment revenue</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NZ$ million</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Australia &amp; New Zealand</td>
<td>China &amp; other Asia</td>
</tr>
<tr>
<td>1H19 Revenue</td>
<td>418.4</td>
<td>171.7</td>
</tr>
<tr>
<td>1H18 Revenue</td>
<td>304.3</td>
<td>114.4</td>
</tr>
<tr>
<td>EBITDA %</td>
<td>45.9%</td>
<td>39.9%</td>
</tr>
<tr>
<td>1H19 EBITDA</td>
<td>192.0</td>
<td>68.4</td>
</tr>
<tr>
<td>EBITDA %</td>
<td>38.3%</td>
<td>42.3%</td>
</tr>
<tr>
<td>% Change Revenue</td>
<td>37.5%</td>
<td>50.1%</td>
</tr>
<tr>
<td>% Change EBITDA</td>
<td>64.9%</td>
<td>41.6%</td>
</tr>
</tbody>
</table>

1 EBITDA is a non-GAAP measure and represents earnings before interest, tax, depreciation and amortisation
Australia goes from strength to strength

- Continued strong performance across all key product segments: liquid milk, infant formula and other nutritional products with strong underlying brand health

- *a2 Milk™* branded fresh milk, our most mature business, achieved record value market share of ~10.8%\(^1\) and revenue growth of 11.7%\(^2\)

- *a2 Platinum®* infant formula remains brand market leader: value share grew from ~32.0% to 35.7%\(^3\)

- No. 1 advertised brand in both milk and infant formula categories

- Other nutritional products revenue grew 37% on prior year
  - Includes Pregnancy and Mānuka products launched in 4Q18

---

\(^1\) Aztec Australian Grocery Weighted Scan 12 months ending 30/12/18. Note, the market share reporting database has been updated in current period to include Costco, Aldi SA & Aldi WA

\(^2\) In AUD

\(^3\) Aztec Australian Grocery and Pharmacy Scan 12 months ending 30/12/18 vs 12 months ending 30/06/18
China performing well

- Infant formula consumption market share growing across China
  - 5.7% Kantar Tier 1 & Key A cities market value share, up from 5.1% as at 30 June 18\(^1\)
  - 5.4% Kantar Tier 1, Key A, B, C & D cities market value share up from 4.7% as at 30 June 18\(^2\)

- Our unique multi-channel strategy continues to provide strength

- China label revenue +83% through Mother Baby Stores (MBS)
  - In-store velocity growth outpacing distribution build
  - China MBS store distribution at ~12,250 stores
  - In-store productivity and building store distribution remain a focus moving forward

- Cross border e-commerce (CBEC) remains a key pathway
  - a2 Platinum\(^\circledR\) brand ranked #2 infant formula brand during 11/11 e-commerce festival across four key e-commerce platforms and a2 Platinum\(^\circledR\) Stage 3 was the top selling product overall\(^3\)

- Accelerating marketing investment to further grow brand awareness, to leverage high loyalty and trust

---

\(^1\) Kantar Infant Formula market consumption tracking of China Tier 1 and Key A cities for 12 months ending 28 December 2018 by value vs 30 June 2018

\(^2\) Kantar Infant Formula market consumption tracking of China Tier 1, Key A, B, C and D cities for 12 months ending 28 December 2018 by value vs 30 June 2018

\(^3\) CBEC ranking provided by platforms: Tmall, JD, Kaola and Yunji
US momentum building

- **a2 Milk™** building sales velocities
  - Revenue more than doubled, up 114.1%\(^2\)
  - Strongest sales velocities in accounts where **a2 Milk™** ranged >2 years

- Distribution increased from ~6,000 stores (June 18) to over 10,000 stores (Dec 18)
  - ~12,400 by end of January 2019
  - Driven by national distribution within Kroger supermarket chain, three new regions within Costco; additional Vons and Safeway stores and further Walmart distribution
  - Rate of distribution growth in January driven by building brand awareness and new store planogram reset timings within the respective retail chains
  - Second half will continue to focus on increased distribution and there will also be a focus on improving in-store productivity in relatively newer stores

- National brand advertising delivering further increases in brand awareness and rate of sale
  - The brand is successfully growing category consumption and sourcing volume across multiple product segments
  - Increased investment in 2H19 to support continued velocity growth; planned investment for FY19 is now approximately US$27 million and we expect to achieve positive monthly EBITDA during 2021

\(^1\) UK & USA segment revenue includes ~$7.8m revenue contribution in 1H19 from infant formula sold to UK exporters (~$8.5m in 1H18)

\(^2\) In USD
**FY19 outlook**

- In the first half the Company has invested strongly in both internal and external capability to better understand our Chinese consumers, channel dynamics and ways of improving brand awareness.

- Following a very strong first half performance, and encouraged by growing market share in China, the Company is now in a position to reinvest the benefits of scale into increased marketing activities in the second half. This is intended to drive brand awareness, predominantly in China, and the US. Increased brand and marketing investment is expected to continue into FY20.

- The Company expects the Group revenue growth rate in the second half to continue broadly in line with the first half. The increased investment in brand building in 2H19 is expected to support revenue growth in FY20 and beyond.

- Second half EBITDA margins will consequently be lower than first half, with full year FY19 EBITDA as a percentage of sales expected to be approximately 31-32%. This is due largely to:
  - Marketing investment in 2H19 to approximately double 1H19
  - Continued investment in building organisational capability

---

1 The Company’s forecast has been calculated using exchange rates as at 31 December 2018.
### Reconciliation of non-GAAP measures

<table>
<thead>
<tr>
<th>NZ$ million</th>
<th>1H19</th>
<th>1H18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia &amp; New Zealand segment EBITDA</td>
<td>192.0</td>
<td>116.4</td>
</tr>
<tr>
<td>China &amp; other Asia segment EBITDA</td>
<td>68.4</td>
<td>48.3</td>
</tr>
<tr>
<td>UK &amp; USA segment EBITDA&lt;sup&gt;1&lt;/sup&gt;</td>
<td>(14.6)</td>
<td>(8.4)</td>
</tr>
<tr>
<td>Corporate EBITDA</td>
<td>(27.4)</td>
<td>(13.4)</td>
</tr>
<tr>
<td>EBITDA&lt;sup&gt;1&lt;/sup&gt;</td>
<td>218.4</td>
<td>143.0</td>
</tr>
<tr>
<td>Depreciation/amortisation</td>
<td>(1.0)</td>
<td>(1.1)</td>
</tr>
<tr>
<td>EBIT&lt;sup&gt;1&lt;/sup&gt;</td>
<td>217.4</td>
<td>141.9</td>
</tr>
<tr>
<td>Net interest income</td>
<td>1.6</td>
<td>0.8</td>
</tr>
<tr>
<td>Income tax expense</td>
<td>(66.3)</td>
<td>(44.2)</td>
</tr>
<tr>
<td>Net profit for the period</td>
<td>152.7</td>
<td>98.5</td>
</tr>
</tbody>
</table>

<sup>1</sup>EBITDA and EBIT are non-GAAP measures. However, the Company believes they assist in providing investors with a comprehensive understanding of the underlying performance of the business.
# Geographic and product segment performance

<table>
<thead>
<tr>
<th></th>
<th>NZ$ million</th>
<th>Australia &amp; New Zealand</th>
<th>China &amp; other Asia</th>
<th>UK &amp; USA</th>
<th>Total Group</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1H19</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liquid milk</td>
<td>67.1</td>
<td>1.1</td>
<td>15.2</td>
<td></td>
<td>83.4</td>
</tr>
<tr>
<td>Infant nutrition</td>
<td>321.6</td>
<td>166.1</td>
<td>7.8</td>
<td></td>
<td>495.5</td>
</tr>
<tr>
<td>Other</td>
<td>29.7</td>
<td>4.5</td>
<td>-</td>
<td></td>
<td>34.2</td>
</tr>
<tr>
<td>TOTAL</td>
<td>418.4</td>
<td>171.7</td>
<td>23.0</td>
<td></td>
<td>613.1</td>
</tr>
<tr>
<td><strong>1H18</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liquid milk</td>
<td>61.1</td>
<td>0.8</td>
<td>7.5</td>
<td></td>
<td>69.4</td>
</tr>
<tr>
<td>Infant nutrition</td>
<td>221.5</td>
<td>111.0</td>
<td>8.5</td>
<td></td>
<td>341.0</td>
</tr>
<tr>
<td>Other</td>
<td>21.7</td>
<td>2.6</td>
<td>-</td>
<td></td>
<td>24.3</td>
</tr>
<tr>
<td>TOTAL</td>
<td>304.3</td>
<td>114.4</td>
<td>16.0</td>
<td></td>
<td>434.7</td>
</tr>
<tr>
<td><strong>% change</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liquid milk</td>
<td>9.8%</td>
<td>45.5%</td>
<td>102.1%</td>
<td></td>
<td>20.2%</td>
</tr>
<tr>
<td>Infant nutrition</td>
<td>45.2%</td>
<td>49.7%</td>
<td>-8.9%</td>
<td></td>
<td>45.3%</td>
</tr>
<tr>
<td>Other</td>
<td>37.2%</td>
<td>66.8%</td>
<td>-</td>
<td></td>
<td>40.4%</td>
</tr>
<tr>
<td>TOTAL</td>
<td>37.5%</td>
<td>50.1%</td>
<td>43.1%</td>
<td></td>
<td>41.0%</td>
</tr>
</tbody>
</table>
China regulatory environment

- The Chinese government issued a number of regulatory updates during the half with respect to e-commerce and CBEC across all products and services. A new e-commerce law (effective 1 Jan 2019) and CBEC policy framework (effective 31 March 2019) together confirmed:
  - A strengthening of compliance obligations for e-commerce operators (domestic and CBEC)
  - English label infant formula and milk powder products can continue to be sold via CBEC as imports for personal use
  - A continuation of preferential tax rates for imports via CBEC bonded warehouse zones
  - An increase to the number of approved CBEC bonded warehouse zones across China

- Synlait Milk facility registrations progressing:
  - Late December 2018, Synlait Milk obtained registration renewal of its Dunsandel plant with the GACC allowing Synlait to continue to export canned infant formula to China; Auckland plant has achieved GACC dairy registration and is progressing with the GACC infant nutrition process

---

1 Provided CBEC participants adhere to the responsibilities as outlined in the policy framework by 31 March 2019
2 General Administration of Customs of the People’s Republic of China
Disclaimer

This presentation dated 20 February 2019 provides additional comment on the Interim Report for the six months ended 31 December 2018 of The a2 Milk Company Limited (the “Company” or “a2MC”) and accompanying information released to the market on the same date. As such, it should be read in conjunction with the explanations and views in those documents.

This presentation is provided for general information purposes only. The information contained in this presentation is not intended to be relied upon as advice to investors and does not take into account the investment objectives, financial situation or needs of any particular investor. Investors should assess their own individual financial circumstances and consider talking to a financial adviser or consultant before making any investment decision.

This presentation is not a prospectus, investment statement or disclosure document, or an offer of shares for subscription, or sale, in any jurisdiction.

Certain statements in this presentation constitute forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company and which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements.

While all reasonable care has been taken in relation to the preparation of this presentation, none of the Company, its subsidiaries, or their respective directors, officers, employees, contractors or agents accepts responsibility for any loss or damage resulting from the use of or reliance on this presentation by any person.

Past performance is not indicative of future performance and no guarantee of future returns is implied or given.

Some of the information in this presentation is based on unaudited financial data which may be subject to change.

All values are expressed in New Zealand currency unless otherwise stated.

All intellectual property, proprietary and other rights and interests in this presentation are owned by the Company.